Drugs / UX-DA001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06778265 | Mar 2025 → Dec 2027 expected | Parkinson disease | Shanghai UniXell Biotechnology Co., Ltd | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Shanghai UniXell Biotechnology Co., Ltd | Results 恰逢五周年，跃赛生物亮相上交会，迎龚正市长巡馆 unixell.com ↗
首例患者接受手术已达15个月，随访数据显示，多名患者运动功能明显改善，震颤症状减轻甚至完全消失，日间“关期”显著缩短，生活质量得到显著提升。 |
| 2025-11-14 | Shanghai UniXell Biotechnology Co., Ltd | Results 跃赛生物亮相MDS，帕金森病创新疗法获国际关注 unixell.com ↗
公布了首例帕金森病患者的6个月随访数据，获得与会专家高度关注。 |
| 2025-06-25 | Shanghai UniXell Biotechnology Co., Ltd | Regulatory 跃赛生物细胞治疗产品UX-DA001荣获美国FDA“快速通道资格”认定！ unixell.com ↗ |
| 2025-04-14 | Shanghai UniXell Biotechnology Co., Ltd | Regulatory 跃赛生物UX-DA001注射液再获FDA临床试验许可——全球首款中美双临床帕金森病自体细胞药物 unixell.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Shanghai UniXell Biotechnology Co., Ltd | 恰逢五周年，跃赛生物亮相上交会，迎龚正市长巡馆 unixell.com ↗ |
| 2025-11-14 | Shanghai UniXell Biotechnology Co., Ltd | 跃赛生物亮相MDS，帕金森病创新疗法获国际关注 unixell.com ↗ |
| 2025-06-25 | Shanghai UniXell Biotechnology Co., Ltd | 跃赛生物细胞治疗产品UX-DA001荣获美国FDA“快速通道资格”认定！ unixell.com ↗ |
| 2025-04-14 | Shanghai UniXell Biotechnology Co., Ltd | 跃赛生物UX-DA001注射液再获FDA临床试验许可——全球首款中美双临床帕金森病自体细胞药物 unixell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UX-DA001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06778265 ↗ |
| Modality | Cell therapy | “UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells)” NCT06778265 ↗ |
| Route | Other | “implanting into bilateral putamina under stereotactic neurosurgery” NCT06778265 ↗ |